Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: Results from a long-term comparative study

Osteoporosis International

Volumn 14, Issue 10, 2003, Pages 801-807

  Ringe, J D ^a   Dorst, A ^a   Faber, H ^a   Ibach, K ^a   Sorenson, F ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Inst for Medical Outcome Research   (Germany)

Author keywords

Alfacalcidol; Bisphosphonate; Bone; Corticosteroid induced osteoporosis; Density; Fracture reduction; Ibandronate

Indexed keywords

ALFACALCIDOL; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CORTICOSTEROID; IBANDRONIC ACID; PREDNISONE;

ADULT; AGED; ARTHRALGIA; ARTICLE; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIARRHEA; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG FATALITY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; EPIGASTRIC PAIN; FEMALE; FEMUR NECK; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; LONG TERM CARE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; PRIORITY JOURNAL; SIDE EFFECT; VERTEBRA FRACTURE;

AGED; BACK PAIN; BODY HEIGHT; BONE DENSITY; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCOCORTICOIDS; HUMANS; HYDROXYCHOLECALCIFEROLS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; OSTEOPOROSIS; SPINAL FRACTURES;

EID: 0345308466     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00198-003-1425-0     Document Type: Article

References (39)

1. Hougardy DM, Peterson GM, Bleasel MD et al (2000) Is enough attention being given to the adverse effects of corticosteroid therapy? J Clin Pharm Ther 25:227-234
2. Walsh LJ, Wong CA, Pringle M et al (1996) Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 313:344-346
3. Adachi JD (1997) Corticosteroid-induced osteoporosis. Am J Med Sci 313:41-49
4. Adinoff AD, Hellister JR (1983) Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 309:265-268
5. Cooper C, Coupland C, Mitchell M (1995) Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis 54:49-52
6. Lukert BP, Raisz LG (1990) Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 112:352-364
7. Reid IR (1997) Glucocorticoid osteoporosis-mechanisms and management. Eur J Endocrinol 137:209-217
8. Sambrook PN, Birmingham J, Kempler S (1990) Corticosteroid effects on proximal femur bone loss. J Bone Miner Res 5:1211-1216
9. Verstraeten A, Dequeker J (1986) Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: effect of low dose corticosteroids. Ann Rheum Dis 45:852-857
10. Ringe JD (1997) Active vitamin D metabolites in glucocorticoid-induced osteoporosis. Calcif Tissue Int 60:124-127
11. Luengo M, Picado C, Del Rio L et al (1991) Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study. Thorax 46:803-806
12. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (2001) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 44:1496-1503
13. Adachi JD, Bensen WG, Brown J et al (1997) Intermittent etidronate therapy to prevent CIO. N Engl J Med 337:382-387
14. Cohen S, Levy RM, Keller M et al (1999) Risedronate therapy prevents corticcsteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42:2309-2318
15. Reid DM, Hughes RA, Laan RF et al (2000) Efficacy and safety of daily risedronate in the treatment of CIO in men and women: a randomized trial. European CIO Treatment Study. J Bone Miner Res 15:1006-1013
16. Adachi JD, Saag KG, Delmas PD et al (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44:202-211
17. Saag KG, Emkey R, Schnitzer TJ et al (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339:292-299
18. Wallach S, Cohen S, Reid DM et al (2000) Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67:277-285
19. de Groen PC, Lubbe DF, Hirsch LJ et al (1996) Esophagitis associated with the use of alendronate. N Engl J Med 35:1016-1021
20. Sharpe M, Noble S, Spencer CM (2001) Alendronate: an update of its use in osteoporosis. Drugs 61:999-1039
21. Adami S, Zamberlan N (1996) Adverse effects of bisphosphonates: a comparative review. Drug Safety 14:158-170
22. Adami S (1999) Ibandronate. Drugs 57:109
23. Roldán EJA, Negri AL, Gador SA (2000) Short-term compliance to daily alendronate treatment in 1877 patients with osteoporosis. The ECMO study. J Bone Miner Res 15 [Suppl 1]:SU411
24. Lombas C, Hakim C, Zanchetta JR (2000) Compliance with alendronate treatment in an osteoporosis clinic. J Bone Miner Res 15 [Suppl 1]:M406
25. Miller NH (1997) Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 102:43-49
26. Colley CA, Lucas LM (1993) Polypharmacy: the cure becomes the disease. J Gen Intern Med 8:278-283
27. Stewart RB, Cooper JW (1994) Polypharmacy in the aged: practical solutions. Drugs Aging 4:449-461
28. Tashkin DP (1995) Multiple dose regimens: impact on compliance. Chest 107:176S-82S
29. Gatley MS (1968) To be taken as directed. J R Coll Gen Pract 16:39-44
30. Huybrechts KF, Ishak KJ, Caro JJ et al (2002) Implications of non-compliance with osteoporosis treatment in actual practice Osteoporos Int 13 [Suppl 3]:S48 (Abstract P107)
31. Delmas PD, Recker RR, Stakkestad JA et al (2002) Oral ibandronate significantly reduces fracture risk in postmenopausal osteoporosis when administered daily or with a unique drug-free interval: results from a pivotal phase III study. Osteoporos Int 13:S15 (Abstract O37)
32. Riis BJ, Ise J, von Stein T et al (2001) Ibandronate: a comparison of oral daily vs intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res 16:1871-1878
33. Thiébaud D, Burckhardt P, Kriegbaum H et al (1997) Three monthly i.v. injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 103:298-307
34. Adami S, Delmas P, Felsenberg D et al (2002) Three-monthly 2 mg intravenous ibandronate bolus injections significantly increase bone mineral density in women with postmenopausal osteoporosis. Osteoporos Int 13 [Suppl 1]: S14 (Abstract 036)
35. Ringe JD, Dorst A, Faber H et al (2003) Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis. Rheumatology 42:743-749
36. Ravn P, Clemmesen B, Riis BJ et al (1996) The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for, prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone 19:527-533
37. Recker RR, Stakkestad JA, Felsenberg D et al (2000) A new treatment paradigm: quarterly Injections of ibandronate reduce the risk of fractures in women with postmenopausal osteoporosis (PMO): results of a 3-year trial. Osteoporos Int 11:S209 (Abstract 565)
38. Reginster JY, de Froidmont C, Lecart MP et al (1999) Alphacalcidol in prevention of glucocorticoid-induced osteoporosis. Calcif Tissue Int 65:328-331
39. Ringe JD (2002) Treatment of glucocorticoid-induced osteoporosis with calcium, vitamin D and D-metabolites. Front Horm Res 30:127-135